Literature DB >> 13268210

Bilateral adrenalectomy in the treatment of cancer of the breast.

T L-Y DAO, C HUGGINS.   

Abstract

Entities:  

Keywords:  ADRENAL GLANDS/surgery; BREAST/neoplasms

Mesh:

Year:  1955        PMID: 13268210     DOI: 10.1001/archsurg.1955.01270170003002

Source DB:  PubMed          Journal:  AMA Arch Surg        ISSN: 0096-6908


× No keyword cloud information.
  9 in total

1.  Surgical endocrine ablation for advanced breast cancer.

Authors:  A P FORREST
Journal:  Postgrad Med J       Date:  1957-08       Impact factor: 2.401

Review 2.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 3.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  Is there a growing role for endocrine therapy in the treatment of breast cancer?

Authors:  P E Lønning
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 5.  Evolution of Medical Approaches and Prominent Therapies in Breast Cancer.

Authors:  Suzann Duan; Iain L O Buxton
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

6.  Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.

Authors:  S Kvinnsland; O Dahl
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 7.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

Review 8.  Prevention and treatment of bone fragility in cancer patient.

Authors:  Silva Ottanelli
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 9.  The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.

Authors:  P E Lønning
Journal:  Ann Oncol       Date:  2010-07-08       Impact factor: 32.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.